On August 14, 2017, the Australian publication Cosmos featured 1997 Paul B. Beeson Emerging Leaders Career Development Award in Aging scholar, 1994 AFAR Research Grant recipient, and AFAR Deputy Scientific Director Nir Barzilai, MD and 2007 Glenn/AFAR Breakthroughs in Gerontology (BIG) Award winner Matt Kaeberlein, PhD.
The article, Going to trial: anti-ageing pills, details the AFAR-managed Targeting Aging with Metformin (TAME) trial and Dr. Kaeberlein’s Dog Aging Project.
Dr. Barzilai tells Cosmos: “If the trial ends up the way we except, that should be enough for the FDA to accept aging per se as a treatable indication.”
Read the full Cosmos article here.
Nir Barzilai, MD is the Director of the Institute for Aging Research and the Director of the Nathan Shock Centers of Excellence in the Biology of Aging at Albert Einstein College of Medicine.
Matt Kaeberlein, PhD is a Professor at the University of Washington School of Medicine and the Director of University of Washington Medicine Nathan Shock Center of Excellence in the Basic Biology of Aging.
For more information on TAME, please see our TAME FAQ page here.
To learn more about the Dog Aging Project, we encourage you to explore our summary of a related feature story in The New York Times here.
